Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:51-59
Published online before print December 27, 2005, doi: 10.1161/CIRCULATIONAHA.105.559724
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
113/1/51    most recent
CIRCULATIONAHA.105.559724v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kee, H. J.
Right arrow Articles by Kook, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kee, H. J.
Right arrow Articles by Kook, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Hypertrophy
Right arrow Physiological and pathological control of gene expression

(Circulation. 2006;113:51-59.)
© 2006 American Heart Association, Inc.


Heart Failure

Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding

Hae Jin Kee, PhD; Il Suk Sohn, MD, PhD; Kwang Il Nam, MD, PhD; Jong Eun Park, BS; Yong Ri Qian, MD; Zhan Yin, PhD; Youngkeun Ahn, MD, PhD; Myung Ho Jeong, MD, PhD; Yung-Jue Bang, MD, PhD; Nacksung Kim, PhD; Jong-Keun Kim, MD, PhD; Kyung Keun Kim, MD, PhD; Jonathan A. Epstein, MD; Hyun Kook, MD, PhD

From the Departments of Pharmacology (H.J.K., Y.R.Q., J.-K.K., K.K.K., H.K.) and Anatomy (K.I.N.), Research Institute of Medical Sciences and Medical Research Center for Gene Regulation, Chonnam National University Medical School (H.J.K., K.I.N., N.K., K.K.K., H.K.), Gwangju, South Korea; The Heart Center (I.S.S., Y.A., M.H.J.) and Research Institute of Clinical Medicine (J.E.P.) of Chonnam National University Hospital, Gwangju, South Korea; National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (Y.-J.B.); and Cardiovascular Institute, University of Pennsylvania, Philadelphia (Z.Y., J.A.E.).

Correspondence to Hyun Kook, MD, PhD, 5 Hak-dong, Dong-ku, Gwangju 501-746, South Korea (e-mail kookhyun{at}chonnam.ac.kr) or Jonathan A. Epstein, MD, 954 BRB II, 421 Curie Blvd, Philadelphia, PA 19104 (e-mail epsteinj@mail.med.upenn.edu).

Received May 3, 2005; revision received August 19, 2005; accepted October 14, 2005.

Background— A number of distinct stress signaling pathways in myocardium cause cardiac hypertrophy and heart failure. Class II histone deacetylases (HDACs) antagonize several stress-induced pathways and hypertrophy. However, cardiac hypertrophy induced by transgenic overexpression of the homeodomain only protein, HOP, can be prevented by the nonspecific HDAC inhibitors trichostatin A and valproic acid, suggesting that alternate targets that oppose class II HDAC function might exist in myocardium. We tested the effects of several HDAC inhibitors, including a class I HDAC-selective inhibitor, SK-7041, on cardiac hypertrophy induced by angiotensin II (Ang II) treatment or aortic banding (AB).

Methods and Results— Cardiac hypertrophy was induced by chronic infusion of Ang II or by AB in mice or rats and evaluated by determining the ratio of heart weight to body weight or to tibia length, cross-sectional area, or echocardiogram. Cardiac hypertrophy induced by Ang II or AB for 2 weeks was significantly reduced by simultaneous administration of trichostatin A, valproic acid, or SK-7041. Echocardiogram revealed that exaggerated left ventricular systolic dimensions were relieved by HDAC inhibitors. HDAC inhibitors partially reversed preestablished cardiac hypertrophy and improved survival of AB mice. The expressions of atrial natriuretic factor, {alpha}-tubulin, ß-myosin heavy chain, and interstitial fibrosis were reduced by HDAC inhibition.

Conclusions— These results suggest that the predominant effect of HDAC inhibition, mainly mediated by class I HDACs, is to prevent cardiac hypertrophy in response to a broad range of agonist and stretch stimuli.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
FASEB J.Home page
S. Chandrasekaran, R. E. Peterson, S. K. Mani, B. Addy, A. L. Buchholz, L. Xu, T. Thiyagarajan, H. Kasiganesan, C. B. Kern, and D. R. Menick
Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes
FASEB J, November 1, 2009; 23(11): 3851 - 3864.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Pang, J. Kothapally, H. Mao, E. Tolbert, M. Ponnusamy, Y. E. Chin, and S. Zhuang
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy
Am J Physiol Renal Physiol, October 1, 2009; 297(4): F996 - F1005.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. Noh, E. Y. Oh, J. Y. Seo, M. R. Yu, Y. O. Kim, H. Ha, and H. B. Lee
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-{beta}1-induced renal injury
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F729 - F739.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. J. Glenn, F. Wang, S. Chen, M. Nishimoto, and D. G. Gardner
Endothelin-Stimulated Human B-Type Natriuretic Peptide Gene Expression Is Mediated by Yin Yang 1 in Association With Histone Deacetylase 2
Hypertension, March 1, 2009; 53(3): 549 - 555.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. Gallo, M. V.G. Latronico, P. Gallo, S. Grimaldi, F. Borgia, M. Todaro, P. Jones, P. Gallinari, R. De Francesco, G. Ciliberto, et al.
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure
Cardiovasc Res, December 1, 2008; 80(3): 416 - 424.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. J. Kee, G. H. Eom, H. Joung, S. Shin, J.-R. Kim, Y. K. Cho, N. Choe, B.-W. Sim, D. Jo, M. H. Jeong, et al.
Activation of Histone Deacetylase 2 by Inducible Heat Shock Protein 70 in Cardiac Hypertrophy
Circ. Res., November 21, 2008; 103(11): 1259 - 1269.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. Trivedi, M. M. Lu, Q. Wang, and J. A. Epstein
Transgenic Overexpression of Hdac3 in the Heart Produces Increased Postnatal Cardiac Myocyte Proliferation but Does Not Induce Hypertrophy
J. Biol. Chem., September 26, 2008; 283(39): 26484 - 26489.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Hu, A. Dandapat, L. Sun, M. R. Marwali, N. Inoue, F. Sugawara, K. Inoue, Y. Kawase, K.-i. Jishage, H. Suzuki, et al.
Modulation of Angiotensin II-Mediated Hypertension and Cardiac Remodeling by Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Deletion
Hypertension, September 1, 2008; 52(3): 556 - 562.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Q. Wei, L. A. Shehadeh, J. M. Mitrani, M. Pessanha, T. I. Slepak, K. A. Webster, and N. H. Bishopric
Quantitative Control of Adaptive Cardiac Hypertrophy by Acetyltransferase p300
Circulation, August 26, 2008; 118(9): 934 - 946.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Su, L. Altucci, and Q. You
Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors
Mol. Cancer Ther., May 1, 2008; 7(5): 1007 - 1012.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. P. Cappola
Molecular Remodeling in Human Heart Failure
J. Am. Coll. Cardiol., January 15, 2008; 51(2): 137 - 138.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. C. Zhao, G. Cheng, L. X. Zhang, Y. T. Tseng, and J. F. Padbury
Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury
Cardiovasc Res, December 1, 2007; 76(3): 473 - 481.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
X. Xu, C.-H. Ha, C. Wong, W. Wang, A. Hausser, K. Pfizenmaier, E. N. Olson, T. A. McKinsey, and Z.-G. Jin
Angiotensin II Stimulates Protein Kinase D-Dependent Histone Deacetylase 5 Phosphorylation and Nuclear Export Leading to Vascular Smooth Muscle Cell Hypertrophy
Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2355 - 2362.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T.-M. Lee, M.-S. Lin, and N.-C. Chang
Inhibition of histone deacetylase on ventricular remodeling in infarcted rats
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H968 - H977.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
R. L. Montgomery, C. A. Davis, M. J. Potthoff, M. Haberland, J. Fielitz, X. Qi, J. A. Hill, J. A. Richardson, and E. N. Olson
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Genes & Dev., July 15, 2007; 21(14): 1790 - 1802.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. A. McKinsey
Derepression of pathological cardiac genes by members of the CaM kinase superfamily
Cardiovasc Res, March 1, 2007; 73(4): 667 - 677.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Lu, P. W. M. Fedak, X. Dai, C. Du, Y.-Q. Zhou, M. Henkelman, P. S. Mongroo, A. Lau, H. Yamabi, A. Hinek, et al.
Integrin-Linked Kinase Expression Is Elevated in Human Cardiac Hypertrophy and Induces Hypertrophy in Transgenic Mice
Circulation, November 21, 2006; 114(21): 2271 - 2279.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Kong, P. Tannous, G. Lu, K. Berenji, B. A. Rothermel, E. N. Olson, and J. A. Hill
Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy
Circulation, June 6, 2006; 113(22): 2579 - 2588.
[Abstract] [Full Text] [PDF]